Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the drug alectinib that can be given safely in children and adolescents with solid tumors or brain and spinal cord cancers that persist after treatment and have a genetic change called an ALK gene fusion. With this gene fusion, the ALK gene attaches to part of another gene.
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Standard chemoradiation may cause severe side effects such as mouth and gut sores, sore throat, and changes in taste.
In this study, researchers are comparing early treatment with venetoclax and obinutuzumab versus delayed treatment with these two medications in patients with newly diagnosed high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are not experiencing symptoms. Starting treatment with these drugs early (before patients have symptoms) may be more effective than delaying treatment until symptoms emerge.
In this study, researchers are comparing selumetinib plus olaparib to selumetinib alone to treat endometrial or ovarian cancer. People in this study have cancer that came back or keeps growing after treatment. In addition, their cancers have a change (mutation or variant) in a RAS gene.
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
Their tumors are also mismatch repair proficient (MMRp)/microsatellite stable (MSS). MMRp/MMS means that their cells are working normally to repair any mistakes made during cell division.
